Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
EBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsReceivables - NetReceivables - OtherWages, Salaries and Other
Ratios

Spero Therapeutics (SPRO) Receivables Refunds (2016 - 2022)

Spero Therapeutics' Receivables Refunds history spans 7 years, with the latest figure at $39000.0 for Q3 2022.

  • For Q3 2022, Receivables Refunds fell 88.6% year-over-year to $39000.0; the TTM value through Sep 2022 reached $39000.0, down 88.6%, while the annual FY2021 figure was $361000.0, 57.33% down from the prior year.
  • Receivables Refunds reached $39000.0 in Q3 2022 per SPRO's latest filing, up from $19000.0 in the prior quarter.
  • In the past five years, Receivables Refunds ranged from a high of $1.9 million in Q1 2018 to a low of $19000.0 in Q2 2022.
  • Average Receivables Refunds over 5 years is $766105.3, with a median of $786000.0 recorded in 2019.
  • The largest YoY upside for Receivables Refunds was 401.35% in 2022 against a maximum downside of 94.51% in 2022.
  • A 5-year view of Receivables Refunds shows it stood at $922000.0 in 2018, then dropped by 14.75% to $786000.0 in 2019, then rose by 7.63% to $846000.0 in 2020, then tumbled by 57.33% to $361000.0 in 2021, then crashed by 89.2% to $39000.0 in 2022.
  • Per Business Quant, the three most recent readings for SPRO's Receivables Refunds are $39000.0 (Q3 2022), $19000.0 (Q2 2022), and $371000.0 (Q1 2022).